Literature DB >> 8504967

Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis.

G N Dalekos1, M N Manoussakis, A C Goussia, E V Tsianos, H M Moutsopoulos.   

Abstract

Ulcerative colitis (UC) is an inflammatory bowel disease of unknown aetiology. In this study, serum samples from 80 patients with UC were studied for the presence of various autoantibodies and soluble interleukin-2 receptor molecules (sIL-2Rs) in an attempt to determine the degree of activation of the immune system in this disease process. Autoantibodies detected included rheumatoid factors (in 5% of patients), antinuclear antibodies (in 51.3%), anti-Ro(SSA) (in 1.3%), anticardiolipin antibodies (IgG and/or IgM classes in 26.3%), anti-double stranded DNA (IgG or IgM classes in 45%), and antineutrophil cytoplasmic antibodies (ANCAs, in 30%). The ANCAs had a perinuclear pattern (p-ANCA) in 95.8%, without anti-myeloperoxidase activity, at least in an enzyme linked immunosorbent assay (ELISA) system. Raised concentrations of sIL-2R were found in 32.5% of patients (26/80, 18 with active and eight with inactive UC). The mean (SD) sIL-2R concentrations were significantly higher in patients with active UC (595 (219) u/ml v 406 (162) u/ml, p = 0.0001) and in patients with ANCAs (584 (177) u/ml in ANCA positive v 447 (212) u/ml in ANCA negative patients, p < 0.01). The sIL-2R concentrations were correlated with increased serum concentrations of C3c (r = 0.23, p < 0.05) or C4 (r = 0.4, p < 0.001) components of the complement system and erythrocyte sedimentation rate (ESR, r = 0.44, p = 0.0001). Platelets, ESR, and C3c were not associated with disease activity (p = 0.06, 0.33 and 0.86) whereas mean (SD) serum concentrations of C4 were higher in active disease (37.4 (11.9) mg/dl v 32.3 (10.3) mg/dl, p < 0.05). The sIL-2Rs had 53% sensitivity and 82.6% specificity for disease activity whereas platelet counts had 53% sensitivity and 58.7% specificity. To conclude, UC is accompanied by an autoimmune response that results in the production of several autoantibodies and cellular immune activation, as shown by the high sIL-2R concentration, is also present. The identification of the target antigen(s) of p-ANCA would possibly act as an indicator of disease activity if this distinct subset of ANCAs can be attributed to the pathogenesis of UC. The sIL-2R concentrations seem to be a useful laboratory marker for assessing activity of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8504967      PMCID: PMC1374185          DOI: 10.1136/gut.34.5.658

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

2.  Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.

Authors:  J E Crabtree; L D Juby; R V Heatley; A J Lobo; D W Bullimore; A T Axon
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

3.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease.

Authors:  A Saxon; F Shanahan; C Landers; T Ganz; S Targan
Journal:  J Allergy Clin Immunol       Date:  1990-08       Impact factor: 10.793

4.  Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.

Authors:  R H Duerr; S R Targan; C J Landers; N F LaRusso; K L Lindsay; R H Wiesner; F Shanahan
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

5.  Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses.

Authors:  R H Duerr; S R Targan; C J Landers; L R Sutherland; F Shanahan
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

6.  Soluble interleukin-2 receptors and autoantibodies in the serum of healthy elderly individuals.

Authors:  M N Manoussakis; E D Stavropoulos; G S Germanidis; C A Papasteriades; K L Garalea; A S Dontas; H M Moutsopoulos
Journal:  Autoimmunity       Date:  1990       Impact factor: 2.815

Review 7.  The hepatitis-lupus connection.

Authors:  I R Mackay
Journal:  Semin Liver Dis       Date:  1991-08       Impact factor: 6.115

Review 8.  The specificity of anti-DNA antibodies in systemic lupus erythematosus.

Authors:  D A Carson
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

9.  Immunological studies in ulcerative colitis. V. Family studies.

Authors:  R Lagercrantz; P Perlmann; S Hammarström
Journal:  Gastroenterology       Date:  1971-03       Impact factor: 22.682

10.  Association of autoantibodies to myeloperoxidase with different forms of vasculitis.

Authors:  J W Tervaert; R Goldschmeding; J D Elema; P C Limburg; M van der Giessen; M G Huitema; M I Koolen; R J Hené; T H The; G K van der Hem
Journal:  Arthritis Rheum       Date:  1990-08
View more
  12 in total

Review 1.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

2.  Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives.

Authors:  C Folwaczny; N Noehl; S P Endres; W Heldwein; K Loeschke; H Fricke
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

3.  Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy.

Authors:  N Custro; G Montalto; V Scafidi; M Soresi; S Gallo; S Tripi; A Notarbartolo
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

Review 4.  The antiphospholipid syndrome and infection.

Authors:  G N Dalekos; K Zachou; C Liaskos
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

5.  Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.

Authors:  Nora Sipeki; Laszlo Davida; Eszter Palyu; Istvan Altorjay; Jolan Harsfalvi; Peter Antal Szalmas; Zoltan Szabo; Gabor Veres; Zakera Shums; Gary L Norman; Peter L Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

6.  Serum immunoglobulin and soluble IL-2 receptor levels in small intestinal overgrowth with indigenous gut flora.

Authors:  S M Riordan; C J McIver; D Wakefield; M C Thomas; V M Duncombe; T D Bolin
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

7.  Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study.

Authors:  Nikolaos K Gatselis; Sarah P Georgiadou; Nikolaos Tassopoulos; Kalliopi Zachou; Christos Liaskos; Angelos Hatzakis; Georgios N Dalekos
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

8.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

9.  IgA anti-b2GPI antibodies in patients with autoimmune liver diseases.

Authors:  Stella Gabeta; Gary L Norman; Nikolaos Gatselis; Christos Liaskos; Panagiotis A Papamichalis; Athanasios Garagounis; Kalliopi Zachou; Eirini I Rigopoulou; George N Dalekos
Journal:  J Clin Immunol       Date:  2008-06-13       Impact factor: 8.317

10.  Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease.

Authors:  Kalliopi Zachou; Eirini Rigopoulou; George N Dalekos
Journal:  J Autoimmune Dis       Date:  2004-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.